HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
HepaRegeniX has raised $24.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2025.
HepaRegeniX's investors include HTGF (High-Tech Gruenderfonds), Wellington Partners, Novo Holdings, Boehringer Ingelheim Venture Fund, Vesalius Biocapital Partners.
HepaRegeniX is headquartered in Ulm, Germany.
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
HepaRegeniX is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HepaRegeniX — Funding & Investors." VCBacked, April 15, 2025, https://www.vcbacked.co/company/heparegenix. Accessed July 21, 2026.
VCBacked. (2025). HepaRegeniX — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/heparegenix
{{cite web |title=HepaRegeniX — Funding & Investors |url=https://www.vcbacked.co/company/heparegenix |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated